Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07046910 · ClinicalTrials.gov registry record · Phase 2

Developing Hyperpolarized Gas MRI Signatures to Detect and Manage Acute Cellular Rejection

A Phase 2 study of Lung Transplant Rejection, sponsored by University of Virginia.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
1
Study location

NCT07046910 is a Phase 2 study of Lung Transplant Rejection that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 60 participants, below the 651-participant average among 6 other Lung Transplant Rejection trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07046910, a Phase 2 study of Lung Transplant Rejection, is actively recruiting participants, sponsored by University of Virginia.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

Lung transplantation (LT) is the only definitive therapy for many patients with end-stage lung diseases. The supply of donors' lungs is the biggest bottleneck to performing a lung transplant, and many patients die while waiting. Acute Cellular Rejection (ACR) is a significant risk factor for developing chronic allograft failure, a primary reason for death in this patient population. These observations highlight the importance of early diagnosis and management of ACR to prevent chronic graft failure. The preliminary results support the idea that Hyperpolarized Gas Magnetic Resonance Imaging has excellent potential to address this clinical gap. This study hypothesizes that optimized hyperpolarized gas magnetic resonance imaging (HGMRI) signatures can detect early pathophysiologic derangements in lung allografts consistent with ACR. This study also hypothesizes that the optimized HGMRI signatures will correlate with single-cell transcriptomic signatures that reflect dysregulated immune responses associated with ACR.

Conditions Studied

Lung Transplant Rejection

Interventions

  • DIAGNOSTIC_TEST Sub study (Active): Two Lung MRI study with two navigational Bronchoscopy
  • DRUG Hyperpolarized Xenon129

Study Locations (1)

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2019-04-01
Est. Completion 2029-03-31
Phase Phase 2

Sponsor

University of Virginia

449 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07046910

The ClinicalTrials.gov registry entry for NCT07046910 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 651-participant average among 6 other Lung Transplant Rejection trials with a reported enrollment target (91% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Transplant Rejection appearing as the primary indexed condition, and to 2 interventions - of which Sub study (Active): Two Lung MRI study with two navigational Bronchoscopy is the first listed.

NCT07046910 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT07046910 about?

NCT07046910 is a clinical study titled "Developing Hyperpolarized Gas MRI Signatures to Detect and Manage Acute Cellular Rejection". Lung transplantation (LT) is the only definitive therapy for many patients with end-stage lung diseases. The supply of donors' lungs is the biggest bottleneck to performing a lung transplant, and many patients die while waiting. Acute Cellular Rejection (ACR) is a significant risk factor for develop...

What is the current status of trial NCT07046910?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2019-04-01. Estimated completion is 2029-03-31.

What conditions does trial NCT07046910 study?

This clinical trial studies the following conditions: Lung Transplant Rejection.

What interventions are being tested in trial NCT07046910?

The interventions under investigation include: Sub study (Active): Two Lung MRI study with two navigational Bronchoscopy (DIAGNOSTIC_TEST), Hyperpolarized Xenon129 (DRUG).

Who is sponsoring clinical trial NCT07046910?

This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07046910 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Transplant Rejection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Transplant Rejection

All registered trials for this condition

Virginia

All trials with a study site in Virginia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.